替米沙坦降压疗效与血管紧张素原启动子区基因多态性关系研究

摘要

目的 探讨替米沙坦降压疗效与血管紧张素原(AGT)启动子区基因多态性的关系.方法 选取2005年6月—2007年1月首都医科大学附属北京天坛医院门诊符合纳入标准的汉族高血压患者148例,均服用替米沙坦单药治疗8周.测定治疗前后人体基本参数、生化指标,比较不同AGT-6 A/G、AGT-20 A/C基因型患者治疗前、后收缩压及其降低幅度、舒张压及其降低幅度.结果 AGT-6 A/G的AA、AG+GG基因型患者治疗后的收缩压、舒张压均低于自身治疗前(P<0.05);不同AGT-6 A/G基因型患者治疗前、后收缩压及其降低幅度、舒张压及其降低幅度比较,差异无统计学意义(P>0.05).AGT-20的A/C AA、AC+CC基因型患者治疗后的收缩压、舒张压均低于自身治疗前(P<0.05);不同AGT-20 A/C基因型患者治疗前、后收缩压及其降低幅度、舒张压及其降低幅度比较,差异无统计学意义(P>0.05).结论 AGT-6 A/G、AGT-20 A/C多态性可能与替米沙坦降压疗效无关.%Objective To estimate the relationship between antihypertensive response to telmisartan and mononucleotide polymorphisms of angiotensinogen (AGT) gene at promoter.Methods Among the outpatients who visited Beijing Tian Tan Hospital, Capital Medical University, from June 2005 to January 2007, 148 Chinese Han hypertensive patients were enrolled according to the inclusion criteria. All of them received telmisartan monotherapy for 8 weeks. Basic human physiological parameters and biochemical indices were measured before and after treatment. Systolic blood pressure (SBP) and diastolic blood pressures (DBP) measured before treatment and after treatment, and the decrease in SBP and DBP after treatment were compared between the patients by AGT-6 A/G genotype and by AGT-20 A/C genotype.Results After treatment, both SBP and DBP decreased significantly in patients with AGT-6 A/G AA genotype and those with AG+GG genotype (P<0.05). There were no significant differences in SBP, DBP measured before and after treatment and the decrease in SBP and DBP after treatment between patients with different genotypes of AGT-6 A/G (P>0.05). Both SBP and DBP were lowered in patients with genotype of AGT-20 A/C AA and those with AC+CC after treatment (P<0.05). There were no obvious differences in SBP, DBP measured before and after treatment and the decrease in SBP and DBP after treatment between patients with different genotypes of AGT-20 A/C (P>0.05). Conclusion Polymorphisms of genotypes of AGT-6 A/G and AGT-20 A/C are not associated with antihypertensive response to telmisartan treatment in Chinese Han hypertensive patients.